OCGN 250117 5.00P (OCGN250117P5000) Stock Options, News & Quotes

US OptionsDetailed Quotes

OCGN250117P5000

Watchlist

4.20
0.000.00%

15min DelayClose Dec 27 16:00 ET

4.20High4.20Low

Intraday

5D
Daily

News

Ocugen Inc. Stock Falls Tuesday, Underperforms Market
MarketWatchDec 24 17:36 ET
Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy
MT NewswiresDec 19 10:39 ET
Express News | Ocugen Inc - Dsmb Approves Continuation of Ocu410 Armada Phase 1/2 Study
ReutersDec 19 06:38 ET
Express News | Ocugen Inc: Ocu410 Has a Very Favorable Safety and Tolerability Profile
ReutersDec 19 06:38 ET
Express News | Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of Ocu410 Armada Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
ReutersDec 19 06:38 ET
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
OcugenDec 19 00:00 ET

Comments

frank Gull_k19

Dec 24 10:47

$Ocugen (OCGN.US)$ bad performance, sell it first

104534386

Dec 21 22:00

$Ocugen (OCGN.US)$ yes i will hold this for long term

Tonyco

Dec 21 18:48

Yikes

Others consist of some losers I will die holding. $La Rosa Holdings (LRHC.US)$ $Stem Inc (STEM.US)$ $Ocugen (OCGN.US)$ $XTI Aerospace (XTIA.US)$

Aladdin Map

Dec 19 09:44

$Ocugen (OCGN.US)$ good news out , les make alittle move up

Trytosaveabit

Dec 19 05:48

Update

$Ocugen (OCGN.US)$ Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewswire· 5 mins ago
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculitis